Transformation of CLL to ALCL: the role of clonality studies in diagnostic molecular haematopathology by unknown
CASE REPORT
Transformation of CLL to ALCL: the role of clonality studies
in diagnostic molecular haematopathology
Richard Colling1,2 & Daniel Royston1,3 & Elizabeth Soilleux1,3
Received: 3 May 2016 /Accepted: 15 July 2016 /Published online: 8 August 2016
Abstract Clonality studies greatly assist in the diagnosis of
challenging haematopathology cases. These robust and
standardised tests aid the detection of clonal lymphoid popu-
lations and may assist in lymphocyte subtyping. In this case
report, a gentleman presented with a high-grade transforma-
tion of a B cell neoplasm which histologically and
immunophenotypically mimicked a T cell anaplastic large-
cell lymphoma. With the aid of T cell and B cell receptor
clonality studies, it was demonstrated that this tumour was
in fact of B cell lineage. This report exemplifies the role of
these increasingly used and relatively new molecular tests in
unusual and difficult lymphoma presentations and highlights
potential pitfalls in the interpretation of their results.
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Introduction
The diagnosis and subtyping of lymphoproliferative disorders
is increasingly aided by evaluating the repertoire of B (Ig) and
T cell (TCR) receptors within lymphoid populations [1, 2]. Ig
and TCR are antigen recognition molecules on the surface of
lymphocytes which are encoded by unique V(D)J exons
formed by somatic recombination of V (variable), D
(determining) and J (joining) gene regions during early matu-
ration in primary lymphoid tissues [3]. Characterising V(D)J
regions present in a lymphoid population not only is extreme-
ly useful in distinguishing reactive (polyclonal) from malig-
nant (clonal) processes but aids in subtyping lymphocytes
with aberrant immunophenotypes [1, 4, 5]. This report aims
to demonstrate the clinical utility of clonality studies in an
unusual case and highlights potential pitfalls when
interpreting molecular data.
Clinical history
A 43-year-old gentleman with no remarkable medical history
presented in 2005 with a lesion of the right buccal mucosa.
This was biopsied and reported as non-specific inflammation.
Eight years later, he presented with an enlarged right-sided
neck lymph nodewhich underwent core biopsy. The histology
of this revealed a dense infiltrate of monomorphic lymphoid
cells which were immunopositive for CD5, CD23 and BCL-2
but immunonegative for CD10 and cyclin-D1. A diagnosis of
a B cell neoplasm, small lymphocytic lymphoma (SLL)/
chronic lymphocytic leukaemia (CLL) was made. A review
of the previous buccal biopsies confirmed a diagnosis of CLL
in these also.Watchful waiting was pursued. One year later, he
presented with a recurrence of CLL at his previous neck site
and underwent bone marrow trephine, which demonstrated
infiltration by CLL, as shown in Fig. 1. The gentleman
remained well with conservative treatment until around a year
later when he re-presented with anaemia, multiple buccal le-
sions and an extensive left scrotal mass.
The gentleman underwent an incisional biopsy of a buccal
lesion and a left orchidectomy with scrotal skin resection.
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Histological examination of both showed an extensive infil-
trate of large, high-grade lymphoid cells with the morpholog-
ical characteristics of anaplastic large-cell lymphoma (ALCL),
as shown in Fig. 2.
Materials and methods
IHC and in situ hybridization (ISH) was initially performed to
subtype the high-grade tumour. B cell receptor (BCR) and T
cell receptor (TCR) clonality studies were carried out due to
the unusual presentation. Clonality studies were performed
using the polymerase chain reaction (PCR)-based
IdentiClone Gene Clonality Assays (Invivoscribe
Technologies, Inc.) [6] which are EuroClonality validated
multiplex protocols.
Results
The left testis was extensively infiltrated by lymphoma, ex-
tending into the scrotal soft tissues and overlying skin. The
malignant cells demonstrated immunopositivity staining for
CD30 and CD7. The Ki67 proliferation fraction was almost
90 %, and anti-c-myc IHC showed staining in around 80 % of
the cells. There was variable weakly positive immunostaining
for CD79a, CD2, CD4, CD8, TIA-1 and BCL-6. IHC for
CD20, CD19, CD5, CD10, CD56, TdT, CD68 (PGM1 clone)
and ALK1 was negative. Chromogenic ISH staining for
Epstein-Barr virus (EBV) was negative. The buccal infiltrate
showed similar morphological and immunophenotypical ap-
pearances, with additional IHC stains showing CD45 positiv-
ity and CD3, Pax5, CD68 (KP1 clone), lysozyme, CD34,
cytokeratin and Melan A negativity.
Multiplexed PCR amplification of extracted DNA from
both the testis and buccal mucosa produced a large isolated
peak with all Ig heavy chain and kappa reaction mixes, as
shown in the example in Fig. 3. These results demonstrated
a clonal rearrangement of both loci within the malignant lym-
phoid population, consistent with a B cell origin.
Amplification of TCR loci performed on the testis, however,
produced a somewhat restricted and irregular profile with in-
consistent fragment sizes between replicates, as shown in
Fig. 4. A number of similar irregular peaks were also identi-
fied in some of the TCR rearrangement results. There was
insufficient material to perform clonality studies on the ante-
cedent CLL, and the patient died shortly after the diagnosis of
ALCL.
Discussion
ALCL is a high-grade lymphoma characterised by large, pleo-
morphic CD30 positive cells typically with a cytotoxic T cell
phenotype [7]. ALCL derived from B cell precursors has been
described and possibly lies within the spectrum of diffuse
large B cell lymphoma (DLBCL) [5, 7–9]. Transformation
of CLL to a high-grade tumour, known as Richter’s transfor-
mation, occurs in around 5–10 % of SSL/CLL. Most com-
monly transformation is to DLBCL; however, Hodgkin lym-
phoma, composite lymphomas and dendritic cell sarcomas
have been reported. Transformation to an ALCL is unusual
[10–12]. Although the tumour shares an anaplastic morphol-
ogy with that of T cell ALCL, the two entities should be
considered distinct in terms of pathogenesis and prognosis.
Fig. 2 Histology of the left scrotal resection showing a dense infiltrate of
large, high-grade lymphoid cells. These cells were immunopositive for
CD30 and CD7 and immunonegative for ALK1, in keeping with ALK-
negative ALCL (H&E; ×425 magnification)
Fig. 1 Histology of the bone marrow trephine biopsy showing a dense
infiltrate of small monomorphic lymphoid cells. These cells were
immunopositive for CD5, CD23 and BCL-2 but immunonegative for
CD10 and cyclin-D1, in keeping with involvement by CLL (H&E;
×425 magnification)
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Overlapping morphology and immunophenotype, however,
make the distinction challenging. Therefore, clonality studies
can be extremely useful in this setting [9, 13]. In particular, in
a case such as this, it is useful to determine whether the ALCL
represents a transformation of the underlying CLL or is a
second independent lymphoma.
Clonality was evaluated historically with labour-intensive
and error-prone Southern blotting. In recent years, PCR-based
assays have gained popularity [1, 2, 4, 14–18]. PCR product
size is dependent upon random assortment during recombina-
tion, and when visualised with GeneScan analysis software
(Applied Biosystems) [19], a reactive population shows a
Gaussian curve distribution [1, 14]. In contrast, neoplastic
populations result in a single peak [1, 14]. The selection of
assay primer targets for a case depends on the clinical question
as well as the quality and quantity of DNA extracted; howev-
er, standardised multiplex assay protocols have been devel-
oped and validated by the EuroClonality consortium
(formally BIOMED-2) and these have resulted in highly sen-
sitive and specific tests which are now considered standard
practice. These are commercially available to all diagnostic
molecular pathology centres [1, 4, 14, 15, 17, 18, 20].
In this case, the gentleman developed a high-grade lym-
phoid malignancy following an indolent 10-year history of
CLL. The patient then rapidly deteriorated and died shortly
a f t e r s u rg e r y. Th e i n i t i a l mo r pho l og i c a l a nd
immunophenotypical impression was that of a de novo
ALCL with a T cell phenotype, raising a possibility of dual
pathology [5, 21, 22]. This would be extremely unusual and,
therefore, PCR-based clonality studies were performed to aid
the diagnosis. This convincingly demonstrated that the popu-
lation was of B cell origin, in keeping with CLL which had
undergone transformation to ALCL and gained an aberrant T
cell phenotype [1, 5]. Interestingly, a number of small irregular
peaks in TCR amplicons were also present, and this could be
misinterpreted as confirming a T cell neoplasm with
Fig. 3 IdentiClone Gene Clonality Assay results from the buccal tumour
showing the PCR GeneScan traces for the Ig heavy chain VH-JH gene
rearrangements (size range 310–360 nt). There is a large clonal peak at
343n, reproducible at both 50 ng (middle trace) and 200 ng (bottom trace)
concentrations compared with the polyclonal control (top trace). The
pseudo-double peak appearance at 343–344 base pairs in the PCRs pro-
duced using 200 ng of DNA template is due to the large amount of PCR
product at 343 base pairs, saturating the electrophoretic capillary system
during GeneScanning, giving an appearance of a second peakwith slower
electrophoretic migration (344 base pairs). Similar clonal peaks were also
demonstrated with Ig heavy chain VH-JH gene rearrangement reaction
mixes at size ranges 250–295 and 100–170 nt, kappa Vk-Kde (size ranges
120–160, 190–210 and 260–300 nt) and kappa Vk-Kde+intron Kde (size
ranges 210–250, 270–300 and 350–390 nt) reaction mixes and were also
present in the same reaction mixes from the buccal tissue tested
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background CLL. However, partial rearrangement of T cell
V(D)J regions within B cell neoplasms is well recognised
[23–25]. Oligoclonal T cell proliferation in immune responses
to lymphoproliferative disorders is also well documented [1,
26, 27], and DNA from these scanty populations, diluted into
the background of tumour and normal tissue, can mimic ma-
lignancy with pseudoclonal peaks at low DNA concentrations
and suspicious oligoclonal profiles at higher concentrations.
These are potential pitfalls when not considered within the full
clinical context [4, 13, 28].
Take-home messages
& Lymphoproliferative disorders with overlapping morpho-
logical and immunophenotypical features continue to pose
a challenge for diagnostic histopathologists.
& PCR-based molecu la r c lona l i ty s tud ies wi th
EuroClonality endorsed assays are being increasingly
used to aid in such diagnoses.
& These studies reveal diagnostically useful information
about clonality in lymphocyte populations and can be use-
ful in subtyping B and T cells.
& Interpretation of these studies must be carried out with
caution and within the full clinical and morphological
context in order to avoid pitfalls.
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Fig. 4 IdentiClone Gene Clonality Assay results from the buccal tumour
showing the PCR GeneScan traces for the TCR Dβ1+Jβ1 (size range
285–325 nt) and Dβ2+Jβ1 (size range 170–210 nt) gene segments. The
Dβ1+Jβ1 segment shows a restricted and irregular polyclonal profile in
both 50 ng (middle trace) and 200 ng (bottom trace) concentrations when
compared with the polyclonal control (top trace). The Dβ2+Jβ1 segment
shows a dominant peak at the 50 ng concentration. This is not
reproducible at 200 ng, but instead shows a restricted and irregular
oligoclonal profile at this concentration. This suggests that there is a
scanty background population of T cells with an oligoclonal (likely
reactive) response, producing a pseudoclonal peak at the low
concentration, due to the low numbers of T cells. Similar findings were
present in several of the other TCR reaction mixes in both the testicular
and the buccal tissue. Several T cell reaction mixes failed to amplify,
presumably due to insufficient T cell derived DNA
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